上海自主研发新冠mRNA疫苗启动I期临床试验
内媒报道,由同济大学附属东方医院转化医学平台与斯微(上海)生物科技有限公司、中国疾病控制中心合作研发的针对预防新冠病毒mRNA疫苗I期临床试验今天(25日)正式启动。标志着上海自主研发mRNA新冠肺炎疫苗正式进入了预防新冠疫情的临床试验行列。
mRNA疫苗原理是让mRNA编码病毒的抗原蛋白序列。mRNA在进入人体细胞内後,会被人体细胞作为模板,来生产病毒的抗原蛋白,从而激活人体的免疫系统,产生保护性抗体。
今年1月4日,该项目获得国家药品监督管理局签发《药物临床试验批件》(批件号2020L00047),应急批准mRNA新型冠状病毒肺炎疫苗开展临床试验。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.